Evidence map›Paper›PMID 18612102›Full record

Trial reportBlood2008

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Graham M Mead, Sharon L Barrans, Wendi Qian, Jan Walewski, John A Radford, Max Wolf, Simon M Clawson, Sally P Stenning, Claire L Yule, Andrew S Jack and 2 more

Registry-linked trialOpen access · bronzeAbstract readClinical TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00040690 (A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma), which is not on this map. Cited by 84 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 3 pooled it
9.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00040690 phase2completednot on this map

A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma

TypeinterventionalSponsorMedical Research CouncilRan2008 to 2008Enrolled120ConditionsLeukemia, LymphomaArmsfilgrastim, cyclophosphamide, cytarabine, doxorubicin hydrochloride, etoposide
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 3 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. [Clinical analysis of 11 cases of high-grade B-cell lymphoma in children].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
    Article
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Graham M MeadSouthampton University Hospitals Trust, Southampton, United Kingdom.
Sharon L Barrans
Wendi Qian
Jan Walewski
John A Radford
Max Wolf
Simon M Clawson
Sally P Stenning
Claire L Yule
Andrew S Jack
UK National Cancer Research Institute Lymphoma Clinical Studies Group
Australasian Leukaemia and Lymphoma Group
MRC Clinical Trials Unit at UCL · GBLeeds General Infirmary · GBPeter MacCallum Cancer Centre · AUThe Christie Hospital · GB

Funding

Medical Research Council MC_U122861381
6 · The paper itself

Abstract

This prospective study aimed to develop reproducible diagnostic criteria for sporadic Burkitt lymphoma (BL), applicable to routine practice, and to evaluate the efficacy of dose-modified (dm) CODOX-M/IVAC in patients diagnosed using these criteria. The study was open to patients with an aggressive B-cell lymphoma with an MKI67 fraction approaching 100%. Immunophenotype and fluorescent in situ hybridization (FISH) were used to separate BL from other aggressive B-cell lymphomas. BL was characterized by the presence of a cMYC rearrangement as a sole cytogenetic abnormality occurring in patients with a germinal center phenotype with absence of BCL-2 expression and abnormal TP53 expression. A total of 128 patients were eligible for the study, of whom 58 were considered to have BL and 70 to have diffuse large B-cell lymphoma (DLBCL). There were 110 clinically fit patients who received dmCODOX-M (methotrexate, dose 3 g/m(2)) with or without IVAC according to risk group. The 2-year progression-free survival was 64% (95% confidence interval [CI] 51%-77%) for BL, 55% (95% CI 42%-66%) for DLBCL, 85% (95% CI 73%-97%) for low risk, and 49% (95% CI 38%-60%) for high-risk patients. The observed differences in outcome and other clinical features validate the proposed diagnostic criteria. Compared with the previous trial LY06 with full-dose methotrexate (6.7 g/m(2)), there was a reduction in toxicity with comparable outcomes. This study was registered at www.clinicaltrials.gov as NCT00040690.

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsBurkitt LymphomaCyclophosphamideCytarabineCytogenetic AnalysisDisease-Free SurvivalDoxorubicinEtoposideHumansIfosfamideImmunophenotypingMethotrexateMiddle AgedTreatment OutcomeVincristineCyclophosphamideCytarabineDoxorubicinEtoposideIfosfamideMethotrexateVincristine

Identifiers

PMID18612102
PMCPMC2532802
OpenAlexW2001985588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.